Senate Republicans Seek Clarity on Mifepristone Safety Review

Sen. Bill Cassidy (R-Louisiana) is at the forefront, leading over a dozen Republican senators in reaching out to FDA Commissioner Marty McCulley. They sent a letter on Thursday inquiring about the recent approval of generic abortion drugs and the FDA’s ongoing research regarding the safety and risks associated with mifepristone, the first medication used in a two-drug regimen for abortions.

Cassidy, who chairs a Senate committee, addressed the topic during a Health, Education, Labor, and Pensions (HELP) speech. He pointed out that McCulley, alongside HHS Secretary Robert F. Kennedy Jr., had previously committed to reviewing the safety data on mifepristone at the start of the year.

The senators expressed their concerns, stating, “Despite this promise to senators at the beginning of the year, the FDA took nearly six months post-confirmation to announce tangible actions on mifepristone’s safety evaluation—doing so quietly in a letter to state attorneys general rather than with any public statement, until a post by Secretary Kennedy on October 2, 2025.” They’ve been frustrated by the almost nonexistent details provided about the review of the drug.

In their letter, the lawmakers demanded that health officials investigate how prior decisions by the Biden and Obama administrations to lift certain safeguards might have influenced mifepristone’s safety. They referenced the removal of a 2016 requirement for prescribers to report non-fatal adverse events related to the drug and the subsequent changes made by the Biden administration, like eliminating in-person dispensing rules and enhancing mail-order abortion access.

They noted that all these modifications happened without sufficient evidence supporting a change from two decades of practice requiring in-person distribution, which was crucial for evaluating potential complications, such as ectopic pregnancies and Rh factor incompatibilities. The absence of in-person requirements also raised concerns about coercion, as the lawmakers cited troubling cases in Texas and Louisiana where women were allegedly forced to take these medications.

Earlier this month, it was reported that the FDA had approved a generic version of the abortion pill, produced by Evita Solutions LLC, which claims a mission to “normalize abortion” and broaden access. The FDA stated that the generic is bioequivalent to the brand-name drug, Mifeprex, produced by Danko Laboratories.

When asked about the safety review for mifepristone, an HHS communications director indicated that the FDA’s discretion around generic drug approvals is quite limited under the law. He mentioned that, by law, approval must be granted if a generic drug is shown to be identical to its branded counterpart, and that independent evidence of safety isn’t mandatory from generic drug applicants.

However, he added that HHS is looking into reported side effects to ensure adequate risk mitigation for mifepristone. “The FDA doesn’t endorse any drug and advises prescribers to adhere to all official labels,” he pointed out.

There are concerns over risks associated with mifepristone if it is used without appropriate medical supervision. The senators are pushing for more transparency regarding the agency’s review processes, questioning the rationale behind the FDA’s previous actions in light of the flaws in the Risk Evaluation and Mitigation Strategies (REMS) framework.

They firmly stated, “This approval does not eliminate the risks for women and does not safeguard them from involuntary drug use.” They also highlighted the contradiction in President Trump’s claims of being the “most pro-life president in history” while advocating for the safety of unborn children.

By October 30, 2025, the senators requested a response from McCulley addressing several inquiries, including President Kennedy’s remarks about the Biden administration’s “distortion” of mifepristone safety data. They seek clarity on the REMS process, data about adverse events, progress on safety studies, and insights into the timelines for new generic drug approvals.

According to recent statistics, 63% of all abortions in the U.S. healthcare system were medical abortions in 2023, translating to an estimated 642,700 pregnancies ending through medical abortion, as reported by the pro-abortion Guttmacher Institute. This share has increased significantly from 53% in 2020 and 39% in 2017, not accounting for abortions obtained outside formal channels.

Mifepristone functions by blocking progesterone, leading to the deterioration of the endometrial lining, cutting off essential nutrients and blood flow to the fetus. Followed by another medication, misoprostol, the process triggers contractions to expel the fetus from the womb.

In closing, Cassidy’s letter garnered support from various Republican senators, urging shared concerns with the FDA’s decision-making regarding the new generic version of the abortion pill.